Results 131 to 140 of about 3,014 (182)

Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next‑generation antibody-drug conjugates (Review). [PDF]

Int J Oncol
Du J, Shen H, Zeng T, Liu W, Xie Y.
europepmc   +1 more source

Correction: Petsas et al. Protein-Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection. <i>Molecules</i> 2025, <i>30</i>, 4240. [PDF]

Molecules
Petsas E, Kiouri DP, Georgiou N, Siasos G, Mavromoustakos T, Chasapis CT.   +5 more
europepmc   +1 more source

Design characteristics of mass balance studies conducted for protein kinase inhibitors. [PDF]

Cancer Chemother Pharmacol
Riechelman B, Bolks R, Oude Munnink TH, Swen JJ, Jansman FGA, Klont F.   +5 more
europepmc   +1 more source

Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Gonzalez-Ericsson PI, Unni N, Jhaveri K, Stringer-Reasor E, Liu Q, Wang Y, Sanchez V, Garcia G, Sanders ME, Lehmann BD, Balko JM, Park B, Rexer BN, Mayer IA, Arteaga CL.   +14 more
europepmc   +1 more source

Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. [PDF]

Onco Targets Ther
Zhang K, Ren Y.
europepmc   +1 more source

<i>FGFR3</i> Gene Alterations and Protein Expression in Paired TURBT and Radical Cystectomy Archival Specimens of Muscle-Invasive Bladder Cancer. [PDF]

Int J Mol Sci
Miyake M, Nishimura N, Ohnishi S, Oda Y, Shimizu T, Owari T, Iida K, Tachibana A, Tomizawa M, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Tanaka N.   +14 more
europepmc   +1 more source

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

New England Journal of Medicine, 2019
Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase inhibitor of FGFR1-4, has shown antitumor activity in preclinical models and in a phase 1 study involving patients with FGFR alterations.In this
Jesus Garcia-donas, Ignacio Duran, Yousef Zakharia   +2 more
exaly   +6 more sources

Erdafitinib in BCG-Treated High-Risk Non-Muscle-Invasive Bladder Cancer [PDF]

Annals of Oncology
Background: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette–Guérin (BCG) treatment and who are ineligible for/refuse radical cystectomy. FGFR alterations
Bladou Franck, Rosa Tambaro, S Triantos
exaly   +5 more sources